__NUXT_JSONP__("/drugs/Lutetium_Lu_177_DOTA-Tetulomab", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A radioimmunoconjugate, which consists of a monoclonal antibody against the cell-surface antigen CD37 covalently linked, via the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. The antibody moiety of lutetium Lu 177 DOTA-tetulomab binds to CD37 on tumor B-cells. Upon internalization, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.",fdaUniiCode:"CPW7BR9UY7",identifier:"C105403",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129819","C2124"],synonyms:["177Lu-DOTA-HH1","177Lu-Dota-Tetulomab","177Lu-HH1",c,"TETULOMAB TETRAXETAN LU-177"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FLutetium_Lu_177_DOTA-Tetulomab",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Lutetium_Lu_177_DOTA-Tetulomab","Lutetium Lu 177 DOTA-Tetulomab","2021-10-30T13:17:46.003Z")));